Documentation of published clinical trials and ... - Institut Hiscia

More documents

Recommendations

Info

References 5.1.4 Uterus, Cervix • Majewsky A., Bentele W. (1963) Über Zusatzbehandlung beim weiblichen Genitalkarzinom. Zentralblatt für Gynäkologie 85 (20), 696–700. Fellmer Ch., Fellmer K.E. (1966) Nachbehandlung bestrahlter Genitalkarzinome mit dem Viscum-album-Präparat „Iscador“. Krebsarzt 21 (3), 174–185. • Fellmer K.E. (1968) A clinical trial of Iscador. British Homoeopathic Journal 57 (1), 43–47. • Leroi R. (1969) Beobachtungen über die zusätzliche Iscador-Therapie in der Behandlung der Frauen mit operiertem und bestrahltem Genitalkarzinom. Gynaecologia 167 (3), 158–170. [Bericht über ein Kollektiv] Portalupi E. (1995) Neoadjuvant treatment in human papilloma virus (HPV)-related cervical intraepithelial neoplasia (CIN) with a mistletoe preparation (Iscador). Internal research report (Università Degli Studi di Pavia). • Grossarth-Maticek R., Ziegler R. (2005) Randomisierte Kohortenstudien im Matched-Pair-Design zur Misteltherapie (Iscador) bei gynäkologischen Karzinomen. In: Scheer R., Bauer R., Becker H., Fintelmann V., Kemper F. H., Schilcher H. (Hrsg.), Fortschritte in der Misteltherapie: Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag 2005, 611–623. The references marked with are included in abstract form in this documentation. © Verein für Krebsforschung, CH-4144 Arlesheim
Survival Urogenital Cancer Uterus 5.1.4.1 Fellmer Ch., Fellmer K.E. (1966) Nachbehandlung bestrahlter Genitalkarzinome mit dem Viscum album Präparat „Iscador“. [Aftercare of genital cancer after radiotherapy with the Viscum album compound „Iscador”.] Krebsarzt 21 (3), 174–185. Study design Design Prospective, controlled study. Patients 790 patients with cancer of the cervix from the I. Universitäts-Frauenklinik München were divided, after radiotherapy into two groups: an Iscador group (81 patients) and a control group (709 patients). Treatment Iscador M c Arg, at different doses, twice respectively 3 times a week s.c., over 5 years. The control group did not receive treatment with Iscador. Length of study 1956–1961. Measurement Survival rate. Most important results 82.7% of the Iscador group survived the 5 years in comparison with 69.1% in the control group. This difference is statistically secured with p = 0.015. The comparability of the groups was recorded. A positive trend in the quality of life in the Iscador group was emphasized. Stage of disease I II III I–III Tab. 1: Results according to stage of disease. Iscador Control Iscador Control Iscador Control Iscador Control n 9 92 45 334 27 283 81 709 3-year survival rate 5-year survival rate 100% 89% 87% 82% 81% 65% 86% 76% 100% 79% 87% 77% 70% 56% 83% 69% Significance no no no yes (p = 0.015) © Verein für Krebsforschung, CH-4144 Arlesheim
Page 1 and 2: Documentation of published clinical
Page 3 and 4: Contents Preface Introduction 1 Imm
Page 5 and 6: Introduction Documentation content
Page 7 and 8: In connection with systematic revie
Page 9 and 10: References 2 DNA-Repair Kovacs E.,
Page 11 and 12: References 3 Quality of Life / Pain
Page 13 and 14: Quality of life / Pain 3.2 Dold U.
Page 15 and 16: Quality of Life / Pain 3.4 Borrelli
Page 17 and 18: Quality of life / Pain 3.6 Bock P.
Page 19 and 20: Quality of Life / Pain 3.6 The effe
Page 21 and 22: From admission to discharge, QoL im
Page 23 and 24: Tumour remissions 4.1 Dold U. et al
Page 25 and 26: Tumour remissions 4.2 Hajto T., Hos
Page 27 and 28: Tumour remissions 4.3 Wagner R. F.
Page 29 and 30: 5 Survival 5.1 Urogenital Cancers 5
Page 31 and 32: Survival Urogenital Cancer Bladder
Page 33 and 34: References 5.1.2 Ovarial • Majews
Page 35 and 36: Survival Urogenital Cancer Ovary 5.
Page 37: References 5.1.3 Body of the Uterus
Page 41 and 42: References 5.1.5 Kidney • Kjaer M
Page 43 and 44: Survival Breast Cancer 5.2.1 Leroi
Page 45 and 46: Survival Breast Cancer 5.2.2 Stage
Page 47 and 48: Survival Breast Cancer 5.2.4 Hellan
Page 49 and 50: Survival Breast Cancer 5.2.5 Grossa
Page 51 and 52: Survival Breast Cancer 5.2.6 [%] Su
Page 53 and 54: Survival Breast Cancer 5.2.7 Fig. 1
Page 55 and 56: References 5.3.1 Stomach • Güncz
Page 57 and 58: Survival Gastrointestinal Cancer St
Page 59 and 60: References 5.3.2 Pancreas • Deliu
Page 61 and 62: References 5.3.3 Rectum / Colon •
Page 63 and 64: Survival Gastrointestinal Cancer Re
Page 71 and 72: References 5.3.4 Liver Metastases
Page 73 and 74: Survival Gastrointestinal Cancer Li
Page 75 and 76: Survival Lung Cancer 5.4.1 Salzer G
Page 77 and 78: Survival Lung Cancer 5.4.2 Salzer G
Page 79 and 80: Survival Lung Cancer 5.4.3 Category
Page 81 and 82: Survival Lung Cancer 5.4.4 Iscador
Page 83 and 84: Survival Lung Cancer 5.4.5 Fig. 2:
Page 85 and 86: Survival Carcinosis of the Pleura 5
Page 87 and 88: References 5.6 Malignant Melanoma
Page 89 and 90:
Survival Melanoma 5.6.2 Schuppli R.
Page 91 and 92:
Survival Melanoma 5.6.3 Efficacy: A
Page 93 and 94:
Safety and Tolerance 6.1 Bock P. R.
Page 95 and 96:
References 7 Systematic Reviews A)
Page 97 and 98:
Systematic Reviews 7.1 Kiene H. (19
Page 99 and 100:
Systematic Reviews 7.1 Publication(
Page 101 and 102:
Systematic Reviews 7.2 Publication
Page 103 and 104:
Systematic Reviews 7.4 Kienle G. S.
Page 105 and 106:
Systematic Reviews 7.5 National Can
Page 107 and 108:
Systematic Reviews 7.5 Publication(
show all

Documentation of published clinical trials and ... - Institut Hiscia

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?